The evidence base for GLP-1 receptor agonist therapy is rapidly expanding beyond adult Type 2 Diabetes Mellitus populations into pediatric and adolescent obesity management, with evidence synthesis methodology maturing in parallel. A Bayesian network meta-analysis pooling 17 randomized controlled trials and 1,230 children and adolescents with obesity establishes a comparative efficacy and safety framework for this drug class in a population historically underrepresented in cardiometabolic drug trials. This mirrors a companion body of evidence in adults—15 cardiovascular outcome trials encompassing 97,173 participants with Type 2 Diabetes Mellitus—suggesting a broader trend of using network meta-analytic techniques to consolidate fragmented trial data into agent-level comparative estimates across the lifespan and across outcome domains (cardiometabolic in youth, cardiovascular in adults).
Within the pediatric analysis, Semaglutide 2.4 mg SC emerges as the top-performing agent for weight-related endpoints, driving the largest reductions in body weight (-18.00 kg), BMI, and waist circumference, while Dulaglutide 1.5 mg shows superior glycemic effects (HbA1c reduction of -1.50%). This divergence hints at an emerging pattern in which different GLP-1 receptor agonist formulations may be preferentially positioned for weight-centric versus glycemic-centric therapeutic goals, even within a single drug class acting through shared incretin-based mechanisms. Cardiometabolic efficacy is evaluated holistically across body weight, BMI, HbA1c, and waist circumference, reflecting a shift toward multidimensional outcome assessment rather than single-endpoint evaluation in obesity pharmacotherapy.
A critical methodological theme threading through this cluster is the reliance on indirect comparisons due to sparse head-to-head trial evidence. Most cross-agent rankings are derived through network-based indirect evidence rather than direct comparative trials, and the resulting agent rankings are explicitly framed as hypothesis-generating rather than confirmatory. This reflects a broader maturation-stage challenge in the GLP-1 receptor agonist field: as the therapeutic class diversifies across formulations, doses, and populations (pediatric obesity, adult diabetes, cardiovascular risk reduction), evidence synthesis via Bayesian and network meta-analytic frameworks is filling evidentiary gaps left by the absence of robust head-to-head trials, while safety profiling remains an essential parallel focus given the novelty of use in younger populations.
Collectively, this cluster signals a trend toward (1) pediatric expansion of GLP-1 receptor agonist indications for obesity, (2) methodological reliance on network meta-analysis and indirect comparison techniques to rank agents amid sparse direct evidence, and (3) a dual-track evidentiary strategy spanning cardiometabolic outcomes in youth and cardiovascular outcomes in adults, positioning GLP-1 receptor agonists as a increasingly differentiated drug class requiring nuanced, population- and endpoint-specific agent selection.